63. Idiopathic thrombocytopenic purpura Clinical trials / Disease details

Clinical trials : 363 / Drugs : 212 - (DrugBank : 43) / Drug target genes : 47 - Drug target pathways : 138

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-002897-19-HU (EUCTR)	02/03/2022	23/12/2021	A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375 in adult participants with Immune thrombocytopenia, a disorder in which there is a reduced amount of platelets in the blood stream which are important for blood to clot normally	AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA - A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375	Primary immune thrombocytopenia MedDRA version: 23.0;Level: LLT;Classification code 10083843;Term: Primary immune thrombocytopenia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Product Name: PF-06835375 Product Code: PF-06835375 INN or Proposed INN: not available Other descriptive name: PF-06835375	Pfizer Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	United States;Czechia;Hungary;Canada;Poland;Australia
2	NCT05070845 (ClinicalTrials.gov)	January 31, 2022	27/9/2021	Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia	AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA	Primary Immune Thrombocytopenia	Biological: PF-06835375	Pfizer	NULL	Not yet recruiting	18 Years	70 Years	All	40	Phase 2	United States;Poland